Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
4.180
-0.070 (-1.65%)
At close: Aug 29, 2025, 4:00 PM
4.240
+0.060 (1.44%)
After-hours: Aug 29, 2025, 6:48 PM EDT
Agenus Employees
Agenus had 316 employees as of December 31, 2024. The number of employees decreased by 73 or -18.77% compared to the previous year.
Employees
316
Change (1Y)
-73
Growth (1Y)
-18.77%
Revenue / Employee
$321,854
Profits / Employee
-$524,310
Market Cap
133.19M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 316 | -73 | -18.77% |
| Dec 31, 2023 | 389 | -144 | -27.02% |
| Dec 31, 2022 | 533 | 92 | 20.86% |
| Dec 31, 2021 | 441 | 82 | 22.84% |
| Dec 31, 2020 | 359 | 31 | 9.45% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AGEN News
- 4 days ago - Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript) - Seeking Alpha
- 6 days ago - Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight - Business Wire
- 13 days ago - Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025 - Business Wire
- 21 days ago - Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress - Business Wire
- 4 weeks ago - Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report - Business Wire
- 5 weeks ago - Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025 - Business Wire
- 2 months ago - Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3 - Business Wire
- 2 months ago - Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology - Business Wire